Drug Profile
BCR/ABL antisense oligonucleotides
Latest Information Update: 20 Jan 2017
Price :
$50
*
At a glance
- Originator Lynx Therapeutics
- Class Antisense oligonucleotides
- Mechanism of Action DNA inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Myeloid leukaemia